The Ibogaine Project
The Ibogaine Project aims to bring real therapeutic solutions to market by furthering the science behind the vast body of anecdotal and empirical knowledge of ibogaine.
Ibogaine is an atypical psychedelic substance that shows potential as an effective medicine for various indications. MINDCURE is making research and drug development opportunities available by synthesizing pharmaceutical grade ibogaine and developing preclinical evidence to support an improved understanding of ibogaine's medical potential.
MINDCURE has developed a number of non-racemic mixtures of ibogaine in the MC-808 program and has filed a provisional patent for these mixtures and their therapeutic use in treating psychiatric and neurological central nervous system (CNS) disorders.
Why We Synthesize
Ibogaine is a psychoactive substance traditionally extracted from the West African iboga shrub.
Research exhibiting ibogaine’s powerful and unique effects on multiple receptors and neurotransmitter systems present exciting opportunities to improve the quality of life for many. These opportunities are limited by the lack of access to a sustainable and consistent supply.
Creating an Opportunity for Psychedelic Researchers
MINDCURE is manufacturing pharmaceutical grade ibogaine to improve access for researchers and clinicians working to create safe and effective treatment options for patients with key indications. The natural source from which ibogaine derives has high natural variability, which poses challenges for the purposes of psychedelic drug research.
With a reliable supply at a known purity, MINDCURE solves the issue of inaccessibility by supplying researchers with the materials needed for preclinical and clinical studies.
Creating an Environmentally Friendly & Sustainable Supply
As a leader in psychedelics, MINDCURE recognizes the value of the iboga plant as a rare and diminishing resource. Our sustainable approach to manufacturing synthetic ibogaine enables us to provide approved research partners and treatment facilities with access to a safe, reliable, and efficacious supply to help drive towards and create better treatment outcomes without further endangering the iboga plant.
MINDCURE is currently on schedule and expects to have GLP supply available for research partners by the end of Q2 2022 and GMP towards year end.
History of Ibogaine
1864
The first scientifically recorded sample is collected in Gabon, brought to France
1889
The genus Tabernanthe H.Bn is established
1901
Crystalized alkaloids are isolated from iboga roots, named ibogaine
1901 – 1905
Ibogaine hydrochloride is used at a dose of 10-30mg/day for anti-fatigue
1930
Lambarene enters market to treat depression, asthenia, convalescence, & infectious disease
1944
Delourme-Houde isolates Tabernanthe
1957
Atropine found to block arousal syndrome caused by ibogaine
1962
Studies confirm ibogaine’s effects on blood pressure and heart rates, reaffirmation that atropine prevents rise in blood pressure but doesn’t impact behavior
1966
Lambarene is removed from market
1969
Ibogaine’s antifatigue and anti-depressant benefits attributed to monoamine oxidase inhibitor
1985 – 1991
Howard Lotsof patents ibogaine for various substance dependencies
2021
MINDCURE successfully synthesizes Ibogaine
2022 Q1
MINDCURE intends to apply for provisional patents
2022 Q1
MINDCURE to start preclinical research
2022 Q3/4
MINDCURE’s GLP to be successfully completed
A Growing Need
The need for ibogaine in both research and therapeutic settings will grow vastly over the years as scientists investigate and discover further indications. The MC-808 program is being developed with a view to treating CNS disorders more safely and effectively than current compositions and methods. Potential therapeutic uses from preliminary data include:
Addiction, including Substance Abuse Disorder
Neuroinflammation, including Traumatic Brain Injury
Anxiety Disorders
Chronic Pain, including Migraine & Cluster Headache
Potential market size for the use of ibogaine:
Addiction
the drug, alcohol and other addictions treatment industry will be worth US$38.2B this year (5.2% annual growth in revenues)
Mood Disorders
the global anxiety and depression market is estimated to reach US$24.4B by 2030
Cognition & Repair
the cognitive enhancement market is estimated to reach US$6.5B by the end of 2023
Preclinical Research Development
MINDCURE is currently in the process of creating strategic preclinical testing models using ibogaine to identify mechanisms of action and expectations, understand cognitive benefits, measure cardiotoxicity and adverse effects, and establish safety measures, dosing, and methods of administration.
Given ibogaine’s complex pharmacology and the way in which it interacts in neurochemistry, our priority in developing preclinical models is in understanding the safety and efficacy for any indication for ibogaine. MINDCURE believes in securing an in-depth understanding of the mechanisms of action through specific preclinical models that outline ibogaine’s dose response on various pathways.
In leveraging the knowledge of ibogaine’s historical uses in the treatment of anxiety and depression as a starting point, our preclinical studies will help us understand, at a deeper level, the compound’s potential and direct our exploration into ibogaine’s potential future uses.
